MedTrace Logo

Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men

NCT05897034 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-06-12

No results posted yet for this study

Summary

Bacterial sexually transmitted infections (STIs) have been steadily increasing in gay, bisexual, and other men who have sex with men (MSM) over the past 2 decades. While that trend started prior to the introduction of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in 2012, HIV PrEP has been associated with increases in sexual contacts and decreases in condom use with an resultant acceleration in the increase of bacterial STIs such as gonorrhea, syphilis, and chlamydia.

Conditions

  • Sexually Transmitted Diseases

Interventions

DRUG

Doxycyclin

Doxycycline is a moderate-spectrum, second-generation tetracycline that is generally well tolerated

DRUG

Pentoxifylline

Pentoxifylline is a vasoactive agent that improves the flow of blood by reducing its viscosity

DRUG

Nitazoxanide 500Mg Oral Tablet

Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections

Sponsors & Collaborators

  • Mostafa Mahmoud Bahaa Clinical Pharmacy Department, Horus University, New Damietta, Egypt

    collaborator UNKNOWN

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-20
Primary Completion
2024-06-20
Completion
2028-06-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05897034 on ClinicalTrials.gov